Navigation Links
Pigs and dogs can bridge gap between mice and humans in developing new therapies
Date:12/16/2008

Human and veterinary medicine could receive a big boost through use of larger animals, especially pigs and dogs, in research, with Europe at the forefront. There is the prospect of bringing drugs to the market more quickly at less cost, as well as accelerating progress in other forms of therapy, notably the use of stem cells in regenerative medicine. The potential in this new field was discussed at a recent workshop organised by the European Science Foundation (ESF), which called for a European pig clinic to facilitate generation and characterisation of models of human disease that would be funded within the EU's Seventh Framework programme, the main source of EU funding for research projects.

The immediate goal in the field is to establish a common standardised way of using animals with clearly defined characteristics (phenotypes), so that results can be compared across Europe. "The workshop showed that there is excellent expertise in individual labs, but the phenotypic tests need to be harmonised and standardised to facilitate comparison of results obtained in different labs," said Angelika Schnieke, one of the workshop's convenors, who holds the chair of Livestock Biotechnology at the Centre of Life Science in Weihenstephan, Germany.

Such standardisation has already been achieved for rodents, particularly the mouse, which is the most widely used animal model at present for human disease research. The extension of such a framework to pigs and dogs will bring great rewards not just for human medicine, but also for treatment of animal diseases. "Large animals offer a link between the classical rodent models and application in the clinic," said Schnieke.

"In view of the close genetic, anatomical and physiological similarities between dog and pig on the one side and human on the other, large animal models are likely to catalyse drug development." As Schnieke added, large animals would also help pursue other therapeutic avenues beyond drug development, including new medical technologies, devices and interventions. Large animals could also be used for research in a number of disease categories, including cancer, metabolic disorders such as obesity, and regenerative therapies, such as use of stem cells to replace damaged heart muscle.

The workshop focused particularly on pigs and dogs because these two animals are quite similar in scale and anatomy to humans, while serving quite complementary functions. Dogs could be used as models for studying the immediate consequences of infectious disease, while pigs could be genetically engineered to mimic certain human conditions, such as deficiencies in the immune system. In such cases pigs would be used like mice are at present to model certain aspects of human immunity or metabolic disorder, but with the advantage of being closer to us in many respects.

"A possible idea is the generation of pigs with a humanised immune system," said Schnieke. "The proof of principle has been shown in the mouse. Immune-deficient mice can be reconstituted with human immune cells and can be used to study immune reactions, for example against tissue xenografts (transplantation of tissue between species, such as pig to human). In theory this could also be possible in pigs. Therefore the generation of immune-deficient pigs is an important goal."

But further funding is required to develop suitable pig models, possibly within a European pig clinic. The workshop also discussed setting up smaller collaborative projects focussed on specific disease areas, with a view to obtaining funding from the ESF. A task force was established to pursue these goals.


'/>"/>

Contact: Angelika Schnieke
schnieke@wzw.tum.de
49-816-171-2004
European Science Foundation
Source:Eurekalert

Related biology news :

1. Building bridges between the clinic and the laboratory
2. Researchers bridge the terahertz gap with new tunable metamaterial
3. Truck-safe bamboo bridge opens in China
4. Scientists find link between inflamed gums and heart disease
5. U of Minnesota researcher finds link between aggression, status and sex
6. Adiponectin is a metabolic link between obesity and bone mineral density
7. Tiny protein provokes healthy bonding between cells
8. Escherichia coli bacteria transferring between humans and mountain gorillas
9. Researchers find link between nicotine addiction and autism
10. Balance between traditional activities, tourism key to sustaining coastal Alaska communities
11. MSU researcher studies ties between cholesterol drugs, muscle problems
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/29/2016)... Nearly one billion matches per second with DERMALOG,s high-speed AFIS    ... ... DERMALOG is Germany's largest Multi-Biometric supplier: The company's Fingerprint ... ... Multi-Biometric supplier: The company's Fingerprint Identification System is part of an efficient ...
(Date:11/21/2016)... VILNIUS, Lithuania , Nov. 21, 2016 /PRNewswire/ ... identification and object recognition technologies, today announced that ... for smart cards was submitted for the ... and successfully passed all the mandatory steps of ... III evaluation is a continuing test of fingerprint ...
(Date:11/15/2016)... , Nov. 15, 2016  Synthetic Biologics, Inc. ... therapeutics focused on the gut microbiome, today announced ... 25,000,000 shares of its common stock and warrants ... at a price to the public of $1.00 ... Synthetic Biologics from the offering, excluding the proceeds, ...
Breaking Biology News(10 mins):
(Date:12/8/2016)... , ... December 08, 2016 , ... ... FrontPanel SDK that provide essential device-to-computer interconnect using USB or PCI Express, announced ... FrontPanel support. The FOMD-ACV-A4 is a small, thin, SODIMM-style module that fits a ...
(Date:12/8/2016)... , ... December 08, 2016 ... ... the commercial launch of flexible packaging for their exceptionally efficient human mesenchymal ... system extends RoosterBio’s portfolio of bioprocess media products engineered to radically streamline ...
(Date:12/8/2016)... Fla. , Dec. 8, 2016  HedgePath ... company that discovers, develops and plans to commercialize ... its shares of common stock were approved for ... will begin trading on the OTCQX, effective today, ... qualify for the OTCQX market, companies must meet ...
(Date:12/7/2016)... , ... December 07, 2016 , ... ... its phase I/II dose escalation and expansion clinical trial for its lead drug ... Austria. The purpose of the trial was to determine the safety, antitumor activity, ...
Breaking Biology Technology: